Nat Med: Clinical study confirms that ADC drug can effectively treat brain metastases from breast cancer

Breast cancer, whose incidence rate ranks first among female malignant tumors all the year round, is called "pink killer.

What's more, breast cancer is prone to metastase.

On August 8, 2022, researchers from the Medical University of Vienna published a research paper entitled: Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial in the top international medical journal Nature Medicin.

This phase 2 clinical trial confirmed that the HER2-targeting antibody-drug conjugate (ADC) drug Trastuzumab deruxtecan can effectively treat or even clear brain metastases in patients with HER2-positive breast cance.

This research opens up new avenues for oncology research and targeted therapy, and is pioneering in the treatment of cancer brain metastase.

Trastuzumab deruxtecan, trade name Enhertu, referred to as T-DX.

This phase 2 clinical trial involved 15 patients (14 women, 1 man) with HER2-positive breast cancer with brain metastase.

Breast cancer is the most common cancer in women, but men also suffer from breast cancer (male breast cancer accounts for less than 1% of breast cancers), and 15% of breast cancers are HER2-positive breast cancers, which are prone to metastasi.

The clinical trial results showed that after treatment, brain metastases shrank in 11 of 15 patients (73%), and brain metastases disappeared completely in 2 patients (13%.

In addition to this extremely positive treatment outcome, the team found that the drug was well tolerated, with no deterioration in participants' brain function or quality of life during the treatment perio.

The research team said that this latest study opens up a new avenue for clinical research and treatment of breast cancer brain metastases, and further studies will be conducted to explore its effect in the treatment of other types of cancer metastase.

It is worth mentioning that on June 5, 2022, the New England Journal of Medicine (NEJM) published a study led by D.

The Phase 3 clinical trial showed that Trastuzumab Deruxtecan extended progression-free survival by approximately 50% and overall survival by 40% in patients with HER2-low-expressing advanced breast cancer compared with patients receiving standard chemotherap.

This is the first time it has been demonstrated that drugs can target the low-expressed HER2 protein and exert a cancer treatment effec.

Original source:

Bartsch, .